Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2020 | The patient’s voice in CAR T-cell regulatory processes

Bregje Verhoeven • 30 Jan 2020
CAR-T Meeting 2020
General CAR-T

Bregje Verhoeven, European Society for Blood & Marrow Transplantation (EBMT), Leiden, The Netherlands, outlines the importance of incorporating the patient’s voice in the regulatory processes of CAR T-cell therapy. Ms Verhoeven discusses the value of patient-reported outcomes as they can describe the quality of life and how it should be incorporated in the health technology assessments (HTAs). This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.

More from Bregje Verhoeven

2:01
Patient advocacy: looking to EBMT 2020
Bregje Verhoeven • 30 Jan 2020
2:20
CAR T-cell therapy access and reimbursement: the patient's perspective
Bregje Verhoeven • 30 Jan 2020
3:08
CAR T-cell therapy: the patient's perspective
Bregje Verhoeven • 26 Apr 2019

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals